Dapagliflozin—redefining treatment of T2DM?

Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently, glycosuria has been regarded only as a consequence of T2DM, but dapagliflozin employs glycosuria a...

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Endocrinology Vol. 7; no. 12; pp. 696 - 697
Main Author:	Chao, Edward C.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-12-2011 Nature Publishing Group
Subjects:	692/699/2743/137/773 692/700/565/1436 Benzhydryl Compounds Care and treatment Dapagliflozin Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy Endocrinology Glucosides - therapeutic use Glycated Hemoglobin A - analysis Health aspects Humans Medicine Medicine & Public Health news-and-views Randomized Controlled Trials as Topic Sodium-Glucose Transporter 2 Sodium-Glucose Transporter 2 Inhibitors Type 2 diabetes United States
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently, glycosuria has been regarded only as a consequence of T2DM, but dapagliflozin employs glycosuria as a mechanism of treatment. Will this paradigm shift gain acceptance?
Bibliography:	SourceType-Other Sources-1 ObjectType-News-1 content type line 66
ISSN:	1759-5029 1759-5037
DOI:	10.1038/nrendo.2011.177